4.8 Article

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

Journal

SCIENCE
Volume 352, Issue 6287, Pages 828-833

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aae0474

Keywords

-

Funding

  1. Intramural Research Programs of the Vaccine Research Center and Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
  2. International AIDS Vaccine Initiative's (IAVI's) Neutralizing Antibody Consortium
  3. Bill & Melinda Gates Foundation
  4. Ministry of Foreign Affairs of Denmark, Irish Aid
  5. Ministry of Finance of Japan
  6. Ministry of Foreign Affairs of the Netherlands
  7. Norwegian Agency for Development Cooperation (NORAD)
  8. UK Department for International Development (DFID)
  9. U.S. Agency for International Development (USAID)
  10. NIH [R01GM079238, P01GM56550, R01GM116654]
  11. U.S. Department of Energy, Basic Energy Sciences, Office of Science, [W-31-109-Eng-38]

Ask authors/readers for more resources

The HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N terminus of the Env-gp41 subunit, is a critical component of the virus-cell entry machinery. Here, we report the identification of a neutralizing antibody, N123-VRC34.01, which targets the fusion peptide and blocks viral entry by inhibiting conformational changes in gp120 and gp41 subunits of Env required for entry. Crystal structures of N123-VRC34.01 liganded to the fusion peptide, and to the full Env trimer, revealed an epitope consisting of the N-terminal eight residues of the gp41 fusion peptide and glycan N88 of gp120, and molecular dynamics showed that the N-terminal portion of the fusion peptide can be solvent-exposed. These results reveal the fusion peptide to be a neutralizing antibody epitope and thus a target for vaccine design.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available